- Home
- CVKD vs CYCN Comparison
CVKD vs CYCN Comparison
Compare CVKD & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- CYCN
- Stock Information
- Founded
- CVKD 2022
- CYCN 2018
- Country
- CVKD United States
- CYCN United States
- Employees
- CVKD N/A
- CYCN N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- CYCN Health Care
- Exchange
- CVKD Nasdaq
- CYCN Nasdaq
- Market Cap
- CVKD 17.1M
- CYCN N/A
- IPO Year
- CVKD 2023
- CYCN N/A
- Fundamental
- Price
- CVKD $15.24
- CYCN $2.91
- Analyst Decision
- CVKD Strong Buy
- CYCN
- Analyst Count
- CVKD 2
- CYCN 0
- Target Price
- CVKD $52.50
- CYCN N/A
- AVG Volume (30 Days)
- CVKD 59.6K
- CYCN 9.9K
- Earning Date
- CVKD 11-08-2024
- CYCN 11-11-2024
- Dividend Yield
- CVKD N/A
- CYCN N/A
- EPS Growth
- CVKD N/A
- CYCN N/A
- EPS
- CVKD N/A
- CYCN 1.22
- Revenue
- CVKD N/A
- CYCN N/A
- Revenue This Year
- CVKD N/A
- CYCN N/A
- Revenue Next Year
- CVKD N/A
- CYCN N/A
- P/E Ratio
- CVKD N/A
- CYCN $2.09
- Revenue Growth
- CVKD N/A
- CYCN N/A
- 52 Week Low
- CVKD $5.40
- CYCN $1.75
- 52 Week High
- CVKD $32.55
- CYCN $5.25
- Technical
- Relative Strength Index (RSI)
- CVKD 60.90
- CYCN 58.67
- Support Level
- CVKD $11.19
- CYCN $2.29
- Resistance Level
- CVKD $15.93
- CYCN $2.70
- Average True Range (ATR)
- CVKD 1.36
- CYCN 0.26
- MACD
- CVKD 0.23
- CYCN 0.03
- Stochastic Oscillator
- CVKD 61.01
- CYCN 96.86
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.